Accelerating Clinical Timelines: Leveraging Ultrasensitive MRD to Navigate Regulatory Pathways
- Accelerating Approvals: The evolving role of MRD as a validated surrogate endpoint in oncology
- The Personalis Ecosystem: Integrating NeXT Personal® and ImmunoID NeXT® for a comprehensive view of cancer dynamics
- The Power of Certainty: Utilizing 100% NPV in MRD-negative populations to guide safe treatment de-escalation